Brief: Orion signs license agreement with Janssen Pharmaceuticals for the development and commercialization of its treatment for alzheimer's disease
19/12/2013 17:52
Dec 19 (Reuters) - Orion Corp 001800.KS : * Signs license agreement with janssen pharmaceuticals, inc. for the development and commercialization of its novel treatment for alzheimer's disease * Entered license deal with janssen pharmaceuticals for development,commercialization of co's alpha-2c adrenoceptor antagonists * Says agreement causes no change on orion's full-year 2013 outlook * As per terms, co will have exclusive commercialization rights in Europe * As per terms, co will grant janssen worldwide exclusive license to develop orm-12741 and other compounds of alpha-2c platform * Source text for Eikon ID:nGNXUZLUHa * Further company coverage 001800.KS ((Bangalore Newsroom; +1 646 223 8780))
Recent news on ORION Holdings
See all newsBrief: Orion Holdings To Buy 82.5 Billion Won Worth Of Shares In Ligachem Biosciences
Refinitiv Newscasts - ‘Halo’ stars walk red carpet for TV series premiere
Brief: ORION Holdings to raise 965.24 bln won in public offering
Brief: Orion to pay annual dividend as 6,000 won/share for FY 2016
Brief: Government Of Singapore buys 5.0 pct stake in Orion